Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401981 | 0.83 | ALDH1A1 (0.52) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL181200 | 0.83 | ALDH1A1 (0.52) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL4464312 | 0.83 | DGAT1 (0.70) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL156346 | 0.81 | DGAT1 (0.68) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL31173096 | 0.80 | HPGD (0.50) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11991639 | 0.79 | DGAT1 (0.66) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL150293 | 0.79 | DGAT1 (1.00) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2349044 | 0.79 | DGAT1 (0.66) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL20560720 | 0.79 | DGAT1 (0.55) | DGAT1LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2095201 | 0.79 | DGAT1 (0.66) | DGAT1LMNAALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 671 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024250573-A1 | REVERSE OSMOSIS MEMBRANE PREPARATION METHOD AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY | 沃顿科技股份有限公司 | 2024-12-12 | — | — | WO | claimed |
| CN-119098067-A | Method for producing reverse osmosis membrane and reverse osmosis membrane produced thereby | 沃顿科技股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-114432900-A | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113264832-A | Method for synthesizing high-purity tert-butyl 2-fluoro-4-bromobenzoate | 南京爱可德夫科技开发有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-109438463-B | O- (4-bromo-2-fluorobenzoyl) glabra with anti-tumor activity, and preparation method and application thereof | 广西中医药大学 | 2021-04-20 | — | — | CN | claimed |
| CN-109438463-A | The bromo- 2- fluoro benzoyl of O-(4- with anti-tumor activity) soil Radix Glycyrrhizae A and preparation method and purposes | 广西中医药大学 | 2019-03-08 | — | — | CN | claimed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
| US-6174839-B1 | AS HERBICIDE | NIHON BAYER AGROCHEM K.K. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5935907-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1999-08-10 | — | — | US | disclosed |
| WO-1999038993-A1 | COMBINATORIAL QUINOLONE LIBRARY | PHARMACOPEIA, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-5856503-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0869123-A2 | Phenylacetylene derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1998-10-07 | — | — | EP | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | DGAT1 3980/4885LMNA 680/4885ALDH1A1 2476/4885 |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | DGAT1 315/4885LMNA 1251/4885ALDH1A1 648/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | DGAT1 4385/4885LMNA 1841/4885ALDH1A1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.